BIDMC-led clinical trial identifies four novel 3D-printed swabs for use in COVID-19 testing

Large-scale production could reduce one obstacle to widespread COVID-19 testing
Beth Israel Lahey Health

Newswise — Boston, Mass. – Public health experts and government leaders agree that easy access to testing for COVID-19 will be critical to managing the virus’ spread and re-opening the world’s economies. However, a shortage of specialized nasopharyngeal (NP) swabs used to collect samples from patients’ noses and throats for diagnosis is one of several bottlenecks in the way of widespread testing. Now a clinical trial conducted by a multi-disciplinary team from Beth Israel Deaconess Medical Center (BIDMC), part of Beth Israel Lahey Health, has identified four novel prototypes of 3D-printed swabs that can be used for COVID-19 testing. A preprint of the team’s manuscript is available on medRxiv.org.* 

Four swab prototypes developed through a highly collaborative effort coordinated by Ramy Arnaout, MD, DPhil, Associate Director of the Clinical Microbiology Laboratories at BIDMC, were tested against a standard NP swab in 230 adults who underwent testing for COVID-19 at BIDMC and volunteered to participate in the study. The four swabs—selected after the review of more than 100 designs—showed excellent concordance with the controls in a clinical trial.

“In this study, we describe the first clinical-trial results of our effort to develop and evaluate multiple new swab prototypes on an extremely tight timeline to address a critical shortage brought about by the COVID-19 pandemic,” said Arnaout. “Through the work of a large and selfless team from health care, academia, and the private sector, it took just 22 days from the time we identified the swab shortage to when our trial clinically validated the first new swab capable of high-throughput manufacture.”

The ongoing clinical trial is the third and final step in an effort that began mid-March, when Arnaout and his fellow directors of BIDMC’s Clinical Microbiology Labs – James Kirby, MD, PhD, and Stefan Riedel, MD, PhD – noted impending swab shortages could hamper testing for COVID-19. Arnaout and colleagues soon had more than 150 novel swab designs made of 45 different materials submitted by 23 companies, laboratories and individuals across the country for BIDMC’s consideration.

“To develop novel, effective alternatives as quickly and safely as possible, we and our collaborators modeled our process on scientific studies that have shown that open and collaborative processes outperform closed or proprietary ones when it comes to time-sensitive innovation,” Arnaout said. “We hope our collective experience can provide a useful roadmap to others working under the pressure of a public health emergency.”

The team established a three-part protocol to evaluate newly-designed prototypes from third parties, as well as existing medical swabs that could be repurposed, to serve as a substitute for standard NP swabs, which are critical to specimen collection for diagnostic testing for SARS-CoV-2, the virus that causes COVID-19.

Among the design considerations was the importance of the roughly six inch swabs being rigid enough to reach potentially infected cells at the back of the nasopharynx but flexible enough not to damage soft and sensitive tissues along the way. Additionally, materials comprising the swab must not interfere chemically with the sensitive genetic test, known as a PCR, used to detect the presence of the virus.

In the first stage of evaluation, experts on the front lines of patient care, including infectious disease specialists and respiratory therapists, provided design feedback on more than 100 prototype swabs developed in less than two weeks by the consortium of collaborators from industry and academia, which included Carbon and Resolution Medical; EnvisionTEC; FormLabs; HP; OPT Industries; Origin; Stanford University; the University of South Florida; and the University of Washington.

In the second stage, Arnaout and colleagues at BIDMC considered the swabs’ potential for large-scale production, sterilization, and packaging. The team also considered variations in the supply chains required for each prototype, “to minimize the risk of future single failure points such as those that contributed to this current swab-shortage crisis,” Arnaout added. The third step was the IRB-approved clinical trial for testing promising prototypes on adult patient-volunteers, including prototypes from Carbon/Resolution Medical, EnvisionTEC, HP and Origin. 

Critical supply chain challenges still remain with respect to COVID testing, but with the trial results announced today, “we are cautiously optimistic that the availability of swabs will soon no longer be a constraint on widespread COVID-19 testing, thanks to an extraordinarily hard-working, talented, and selfless group, including dozens of people at BIDMC, who came together from all over the country to do this work,” Arnaout said.

“When the virus first emerged, one of the great barriers facing hospitals was the limited availability of testing,” said Gyongyi Szabo, MD, PhD, Chief Academic Officer for Beth Israel Deaconess Medical Center and Beth Israel Lahey Health. “BIDMC’s mission as an academic medical center includes to bring innovation from our laboratories to the bedside. This effort demonstrates the power of successful collaboration among BIDMC, academic and industry partners to respond to the extraordinary challenges of the COVID-19 pandemic.”

Arnaout thanks his team and other collaborators and colleagues, including Abigail Bakken, Craig Broady, John Burpo, Cody Callahan, Alisa Chau, Annie Cheng, Monique Cole, Daniel Davis, Summer Decker, Joseph DeSimone, Zachary Fitts, Annette Friskopp, Ric Fulop, Jonathan Goldie, Grant Michael Gonzalez, Pavel Gorelik, Alex Green, Markus Greiner, Marie Herring, Jenny Hu, Matthew Hurley, Lan Huynh, Don Ingber, Pawan Jolly, Hardik Kabaria, James Kirby, David Lakatos, Rose Lee, Christina Lexinger-Holahan, Ben Linville-Engler, Lorinda Longhi, Ofer Mazor, Restituto Miranda, Goutam Reddy, Stefan Riedel, Karen Robinson, Kit Parker, Oren Mechanic, Richard Novak, Jifei Ou, Michael Papish, Shawn Patterson, Steve Pollack, Chris Prucha, Christian Reed, Isabel Sanz, Adama Sesay,  Al Siblani, Kenneth P. Smith, Lihua Zhao and Kate Zulauf.

* Note: The contents of this press release reflect the findings of an updated version of the manuscript submitted to but not yet available on medRxiv.org.  The updated manuscript is available upon request.  Please contact Jacqueline Mitchell (BIDMC) at: [email protected].   

About Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. For more information, visit www.bidmc.org

BIDMC is part of Beth Israel Lahey Health, a new health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,000 physicians and 35,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.

###

SEE ORIGINAL STUDY



Filters close

Showing results

2130 of 5849
Newswise: Pandemic-Era Crowdfunding More Common, Successful in Affluent Communities
Released: 16-Jun-2021 5:05 PM EDT
Pandemic-Era Crowdfunding More Common, Successful in Affluent Communities
University of Washington

A new University of Washington study of requests and donations to the popular crowdfunding site GoFundMe, along with Census data, shows stark inequities in where the money went and how much was donated.

Newswise: In Show of COVID-19 Vaccine Confidence, 96% of America’s Ophthalmologists Already Vaccinated
Released: 16-Jun-2021 3:50 PM EDT
In Show of COVID-19 Vaccine Confidence, 96% of America’s Ophthalmologists Already Vaccinated
American Academy of Ophthalmology (AAO)

The American Academy of Ophthalmology is calling on its members to continue to build confidence in COVID-19 vaccines and encourage people to get vaccinated, including their staff.

Newswise: Biophysical Study Sheds Light on Potentially Druggable Process of SARS-CoV-2 Replication
Released: 16-Jun-2021 12:50 PM EDT
Biophysical Study Sheds Light on Potentially Druggable Process of SARS-CoV-2 Replication
National Institute of Biomedical Imaging and Bioengineering

This study investigates how the nucleocapsid protein, or N protein, of the SARS-CoV-2 virus packages the viral genome.

Newswise: ‘Wonder material’ can be used to detect COVID-19 quickly, accurately
Released: 16-Jun-2021 11:55 AM EDT
‘Wonder material’ can be used to detect COVID-19 quickly, accurately
University of Illinois at Chicago

Researchers at the University of Illinois Chicago have successfully used graphene — one of the strongest, thinnest known materials — to detect the SARS-CoV-2 virus in laboratory experiments.

Newswise: UCLA-led Research Finds Connections Between Air Quality and COVID Vulnerability
Released: 16-Jun-2021 11:05 AM EDT
UCLA-led Research Finds Connections Between Air Quality and COVID Vulnerability
UCLA Fielding School of Public Health

Even as governments across the United States consider lifting mask mandates and relaxing preventative measures as vaccination numbers creep up, new research from a UCLA-led team has found that such basic techniques significantly reduce the risk of getting COVID-19. In addition, the research found that U.S. counties with higher exposures to poor air quality, historically, saw higher county-level COVID-19 mortality rates in 2020.

Newswise: Story Tips from Johns Hopkins Experts on COVID-19
Released: 16-Jun-2021 11:00 AM EDT
Story Tips from Johns Hopkins Experts on COVID-19
Johns Hopkins Medicine

NEWS STORIES IN THIS ISSUE: - Stressed About “Returning to Normal”? Here Are Tips to Ease Into the Transition - Be Your Brother’s Keeper: Steps for Faith-Based Communities to Reopen Safely

Released: 16-Jun-2021 8:00 AM EDT
Two COVID-19 Vaccines Show Safety, Strong Immunity in Infant Model
University of North Carolina School of Medicine

The Moderna mRNA vaccine and a protein-based vaccine candidate elicited durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical research. There were no adverse effects.

Newswise: Data and Safety Review Board Reports How it Monitored the COVID-19 Vaccine Trials
Released: 15-Jun-2021 2:55 PM EDT
Data and Safety Review Board Reports How it Monitored the COVID-19 Vaccine Trials
University of Alabama at Birmingham

Evaluation of three vaccine candidates during the COVID-19 pandemic fell to 12 experts of the federally appointed COVID-19 Vaccine Data and Safety Monitoring Board. This team has now taken the unusual step of publishing details of their review process in The Journal of Infectious Diseases.

Released: 15-Jun-2021 1:55 PM EDT
NCCN Policy Summit Explores How COVID-19 Pandemic Can Lead to Improvements in Cancer Care
National Comprehensive Cancer Network® (NCCN®)

NCCN Policy Summit examines the impact of the past year on oncology policy in the U.S., such as resuming recommended screening and clinical trials, applying health innovations from the COVID-19 pandemic to cancer treatment, and addressing systemic inequalities that lead to disparities in outcomes.


Showing results

2130 of 5849

close
13.60866